Investegate announcements from F. Hoffmann-La Roche Ltd, New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showed Evrysdi
Girl set for wheelchair by three still standing thanks to £64,000 injections hulldailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hulldailymail.co.uk Daily Mail and Mail on Sunday newspapers.